期刊文献+

Denosumab in bone-metastatic prostate cancer: known effects on skeletal'related events but unknown effects on quality of life

Denosumab in bone-metastatic prostate cancer: known effects on skeletal'related events but unknown effects on quality of life
下载PDF
导出
摘要 The purpose of new pharmaceuticals is to improve how patients feel, function or survive. Exceptions exist when surrogates are developed and we know that those surrogates correlate well with one of the above. Hypercholesterolemia is a well-accepted example. We know that high cholesterol is a reasonable indicator that results in increased risk of strokes and heart attacks. Thus, we treat hypercholesterolemia in hopes that our patients' health will improve. The purpose of new pharmaceuticals is to improve how patients feel, function or survive. Exceptions exist when surrogates are developed and we know that those surrogates correlate well with one of the above. Hypercholesterolemia is a well-accepted example. We know that high cholesterol is a reasonable indicator that results in increased risk of strokes and heart attacks. Thus, we treat hypercholesterolemia in hopes that our patients' health will improve.
作者 Oliver Sartor
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2011年第4期612-613,共2页 亚洲男性学杂志(英文版)
  • 相关文献

参考文献3

  • 1Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner Pet al.; Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002: 94: 1458-68. 被引量:1
  • 2http://www.fda.gov/downloads/Drugs/G uidanceCom pliance Regulatorylnformation/Guidances/UCM 193282.pdf (ac- cessed 20 March 2011). 被引量:1
  • 3Fizazi K, Carducci M, Smith M, Damiao R, Brown J et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet2011: 377: 813-22. 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部